Literature DB >> 25701352

Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.

Jamil Akkad1, Sylvia Bochum, Uwe M Martens.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and continues to be a major healthcare concern. Molecular heterogeneity of CRC is believed to be one of the main factors responsible for the considerable variability in treatment response. With the recent development of powerful genomic technologies, novel insights in tumor biology of CRC have now been provided, facilitating the recognition of new molecular subtypes with prognostic and predictive implications.
PURPOSE: The purpose of this review article is to summarize current knowledge about genomic, epigenomic, and proteomic characteristics of CRC, as well as their implications for biomarker identification and individualized targeted therapy.
CONCLUSION: Supplementing the findings from several previous studies, the Cancer Genome Atlas (TCGA) project recently finalized the systematic characterization of CRC resulting in the first tumor dataset with complete molecular measurements at DNA, RNA, and protein levels. The challenge now is to translate these findings into a robust and reproducible CRC classification system linking molecular features of the tumor to precision medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25701352     DOI: 10.1007/s00423-015-1276-0

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  130 in total

1.  The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

Authors:  Claudia Esposito; Anna Maria Rachiglio; Maria Libera La Porta; Alessandra Sacco; Cristin Roma; Alessia Iannaccone; Fabiana Tatangelo; Laura Forgione; Raffaella Pasquale; Americo Barbaro; Gerardo Botti; Fortunato Ciardiello; Nicola Normanno
Journal:  Cancer Biol Ther       Date:  2013-09-23       Impact factor: 4.742

2.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

Review 3.  The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.

Authors:  Rodrigo Dienstmann; Ramon Salazar; Josep Tabernero
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

4.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

5.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

Authors:  Herbert I Hurwitz; Niall C Tebbutt; Fairooz Kabbinavar; Bruce J Giantonio; Zhong-Zhen Guan; Lada Mitchell; Daniel Waterkamp; Josep Tabernero
Journal:  Oncologist       Date:  2013-07-23

6.  Molecular staging for survival prediction of colorectal cancer patients.

Authors:  Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 7.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

Authors:  Ninel Azoitei; Christopher M Hoffmann; Jana M Ellegast; Claudia R Ball; Kerstin Obermayer; Ulrike Gößele; Britta Koch; Katrin Faber; Felicitas Genze; Mark Schrader; Hans A Kestler; Hartmut Döhner; Gabriela Chiosis; Hanno Glimm; Stefan Fröhling; Claudia Scholl
Journal:  J Exp Med       Date:  2012-03-26       Impact factor: 14.307

10.  Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Authors:  Sumitra Mohan; Ellen Heitzer; Peter Ulz; Ingrid Lafer; Sigurd Lax; Martina Auer; Martin Pichler; Armin Gerger; Florian Eisner; Gerald Hoefler; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  PLoS Genet       Date:  2014-03-27       Impact factor: 6.020

View more
  7 in total

1.  Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases.

Authors:  Ibrahim Meteoglu; Ibrahim Halil Erdogdu; Pars Tuncyurek; Adil Coskun; Nil Culhaci; Muhan Erkus; Sabri Barutca
Journal:  Gastroenterol Res Pract       Date:  2015-04-06       Impact factor: 2.260

2.  Recombinant lentivirus with enhanced expression of caudal-related homeobox protein 2 inhibits human colorectal cancer cell proliferation in vitro.

Authors:  Sai He; Xue-Jun Sun; Jian-Bao Zheng; Jie Qi; Nan-Zheng Chen; Wei Wang; Guang-Bing Wei; Dong Liu; Jun-Hui Yu; Shao-Ying Lu; Hui Wang
Journal:  Mol Med Rep       Date:  2015-04-03       Impact factor: 2.952

Review 3.  Strategy to targeting the immune resistance and novel therapy in colorectal cancer.

Authors:  Wang Gang; Jun-Jie Wang; Rui Guan; Sun Yan; Feng Shi; Jia-Yan Zhang; Zi-Meng Li; Jing Gao; Xing-Li Fu
Journal:  Cancer Med       Date:  2018-04-15       Impact factor: 4.452

Review 4.  Colorectal Cancer: From Genetic Landscape to Targeted Therapy.

Authors:  Mouade El Bali; Joaira Bakkach; Mohcine Bennani Mechita
Journal:  J Oncol       Date:  2021-07-06       Impact factor: 4.375

Review 5.  Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.

Authors:  Heng Fong Seow; Wai Kien Yip; Theodora Fifis
Journal:  Onco Targets Ther       Date:  2016-03-31       Impact factor: 4.147

6.  Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target.

Authors:  Ling Ye; Sheng-Tao Lin; Yu-Shuai Mi; Yuan Liu; Yang Ma; Hui-Min Sun; Zhi-Hai Peng; Jun-Wei Fan
Journal:  Tumour Biol       Date:  2016-09-10

7.  In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers.

Authors:  Xin Ku; Yan Xu; Chunlin Cai; Yili Yang; Long Cui; Wei Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2019-11-04       Impact factor: 2.916

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.